• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by NewcelX Ltd.

    12/11/25 9:22:26 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NCEL alert in real time by email
    6-K 1 ea0269296-6k_newcelx.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of December 2025 (Report No. 1)

     

    Commission File Number: 001-39957

     

    NEWCELX LTD.

    (Translation of registrant’s name into English)

     

    The Circle 6

    8058 Zurich, Switzerland

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    ☒ Form 20-F ☐ Form 40-F

     

     

     

     

     

     

    CONTENTS

     

    On December 11, 2025, NewcelX Ltd., a corporation incorporated under the laws of Switzerland, issued a press release titled: “NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China.” A copy of this press release is furnished herewith as Exhibit 99.1.

     

    1 

     

     

    EXHIBIT INDEX

     

    Exhibit

    Number

      Description of Document
    99.1   Press release titled: “NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China”

     

    2 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      NewcelX Ltd.
           
    Date: December 11, 2025 By: /s/ Ronen Twito
        Name: Ronen Twito
        Title: Chief Executive Officer

     

    3

     

    Get the next $NCEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NCEL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NCEL
    SEC Filings

    View All

    SEC Form 6-K filed by NewcelX Ltd.

    6-K - NewcelX Ltd. (0001783036) (Filer)

    12/11/25 9:22:26 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NewcelX Ltd.

    6-K - NewcelX Ltd. (0001783036) (Filer)

    11/20/25 4:16:20 PM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by NewcelX Ltd.

    EFFECT - NewcelX Ltd. (0001783036) (Filer)

    11/19/25 12:15:10 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

    Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company's expanding position in neurology and metabolic diseases ZURICH, Dec. 11, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL), a next-generation biotechnology company developing advanced cell-therapy and neuroscience-driven therapeutics, today announced the publication of a major international patent application in China covering a new class of quinazoline, benzothiazine, and benzoxazine derivatives (DOXA) for the treatment of neurological diseases. This publication marks an import

    12/11/25 7:00:00 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

    ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board ("SAB").   Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and

    11/17/25 7:00:00 AM ET
    $NCEL
    $NLSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewcelX CEO Issues Letter to Shareholders

    ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, integrating regenerative medicine and neuroscience expertise within a unified platform, today issued a letter to its shareholders.     Dear Shareholders, The future of NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX" or the "Company") begins now. Our Company stands at a pivotal moment, where years of scientific innovation are converging with what we view as real opportunity. We believe that the next 12 months are positioned to redefine what we can achieve for patients and create meaningful valu

    11/4/25 7:00:00 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCEL
    Leadership Updates

    Live Leadership Updates

    View All

    NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

    ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board ("SAB").   Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and

    11/17/25 7:00:00 AM ET
    $NCEL
    $NLSP
    Biotechnology: Pharmaceutical Preparations
    Health Care